Multicenter retrospective cohort study of neoadjuvant chemotherapy followed by interval debulking surgery for advanced endometrial cancer

The mainstay of endometrial cancer treatments is surgical resection, followed by adjuvant treatment if necessary. There is no consensus on the management of unresectable metastatic endometrial cancer. A retrospective study in four centers in South-Korea found that neoadjuvant chemotherapy followed by interval debulking surgery may be a treatment option for unresectable metastatic endometrial cancer. The median progression-free survival was 19.7 months, and the 3-year overall survival rate was 69.7%.